Skip to main content
Premium Trial:

Request an Annual Quote

Ariadne Chosen as Partner in Affymetrix's Gene Expression Training Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix has chosen Ariadne as an exclusive partner of the Affymetrix University Gene Expression Training Program, Ariadne announced Wednesday.

As a result, the Rockville, Md.-based bioinformatics software company will provide education on pathway analysis during training programs held by Affymetrix University in North America and Europe. Course registrants will also be given a 30-day license to Ariadne's Pathway Studio analysis software following training.

Financial and other terms of the agreement were not disclosed.

According to Ariadne, "Pathway Studio enables pathway analysis of the entire probe list, associating genes into like-functioned or like-associated biological properties using advanced data analysis algorithms." It allows researchers to analyze and visualize results individually or in an integrated workflow, the company added.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.